Liminatus Pharma to Acquire InnocsAI in $320M Stock Deal, Issuing 1.6 Billion Shares
LIMN sits 38% above its 52-week low of $0.159 on light trading volume (0.3× avg).
Summary
Liminatus Pharma has announced a definitive agreement to acquire InnocsAI through a merger, a highly transformative event for the company. The deal involves issuing 1.6 billion shares of Liminatus common stock at $0.20 per share, plus contingent value rights, valuing the transaction at approximately $320 million. This represents an extraordinary level of dilution for existing shareholders, given Liminatus's current market capitalization of roughly $8.4 million. The acquisition aims to expand Liminatus's CAR-T and antibody oncology platform, but the financial terms suggest a de facto reverse merger where InnocsAI effectively takes control of the public entity. This news follows Liminatus's recent 10-Q filing, which reported a significantly widened net loss and expressed substantial doubt about its ability to continue as a going concern. Traders must recognize this as a fundamental restructuring that will drastically alter the company's ownership structure and the value of existing equity.
At the time of this announcement, LIMN was trading at $0.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.4M. The 52-week trading range was $0.16 to $33.66. This news item was assessed with negative market sentiment and an importance score of 10 out of 10. Source: Wiseek News.